Prader

Bradford White Water Heaters announces connected water heater technology

Retrieved on: 
Wednesday, January 4, 2023

AMBLER, Pa., Jan. 4, 2023 /PRNewswire/ -- Bradford White Water Heaters, an industry-leading American manufacturer of water heaters, boilers and storage tanks, introduces Bradford White Connect™, an external adapter providing app-driven monitoring technology for the AeroTherm® heat pump water heater (HPWH) series.

Key Points: 
  • AMBLER, Pa., Jan. 4, 2023 /PRNewswire/ -- Bradford White Water Heaters , an industry-leading American manufacturer of water heaters, boilers and storage tanks, introduces Bradford White Connect™, an external adapter providing app-driven monitoring technology for the AeroTherm® heat pump water heater (HPWH) series.
  • "The Bradford White Connect™ platform offers homeowners a range of convenient options so they can manage their AeroTherm® unit wherever they are," said Louise Prader, senior director, product management for Bradford White.
  • Contractors can use Bradford White Connect™ to monitor in-service Aerotherm HPWHs, analyze their performance, and set alerts for water heater errors.
  • Bradford White Water Heaters is a full-line manufacturer of residential, commercial and industrial water heating, space heating, combination heating and storage products.

Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study

Retrieved on: 
Thursday, July 22, 2021

Based on the feedback received, Radius plans on initiating a pivotal Phase 2/3 global study for patients with PWS.

Key Points: 
  • Based on the feedback received, Radius plans on initiating a pivotal Phase 2/3 global study for patients with PWS.
  • Radius plans to initiate the pivotal Phase 2/3 study, to be branded as SCOUT (Synthetic Cannabidiol Oral Solution), by end of this year or early first quarter of 2022.
  • With this current initiation timeline, it is anticipated top line results would be available in the second half of 2024.
  • Radius is initially targeting Prader-Willi syndrome (PWS) and anticipates initiating a seamless pivotal Phase 2/3 study for patients with PWS in the second half of 2021.

Global Prader-Willi Syndrome (PWS) Clinical Trials Review, H1, 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 10, 2021

The "Prader-Willi Syndrome (PWS) - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prader-Willi Syndrome (PWS) - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Prader-Willi Syndrome (PWS) - Global Clinical Trials Review, H1, 2021" provides an overview of Prader-Willi Syndrome (PWS) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Prader-Willi Syndrome (PWS).
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
    Facilitates clinical trial assessment of the indication on a global, regional and country level
    Clinical Trials by G7 Countries: Proportion of Prader-Willi Syndrome (PWS) to Genetic Disorders Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Prader-Willi Syndrome (PWS) to Genetic Disorders Clinical Trials

Soleno Therapeutics to Host Webinar Highlighting DCCR for Treatment of Prader-Willi Syndrome at European Congress on Endocrinology 2021

Retrieved on: 
Friday, May 21, 2021

Dr. Gevers served as the Coordinating Investigator for DESTINY PWS for sites in the UK.\nThe webinar can be accessed by registered delegates attending the European Congress on Endocrinology.

Key Points: 
  • Dr. Gevers served as the Coordinating Investigator for DESTINY PWS for sites in the UK.\nThe webinar can be accessed by registered delegates attending the European Congress on Endocrinology.
  • Hyperphagia can lead to significant morbidities (e.g., obesity, diabetes, cardiovascular disease) and mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior).
  • There are currently no approved therapies to treat the hyperphagia/appetite, metabolic, cognitive function, or behavioral aspects of the disorder.
  • The company\xe2\x80\x99s lead candidate, DCCR Extended-Release tablets, once-daily oral tablets for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program.

Soleno Therapeutics to Participate in the Oppenheimer Rare & Orphan Disease Summit

Retrieved on: 
Thursday, May 20, 2021

b'REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (\xe2\x80\x9cSoleno\xe2\x80\x9d) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that\xc2\xa0Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 1:15 PM Eastern Time.\nSoleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Key Points: 
  • b'REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (\xe2\x80\x9cSoleno\xe2\x80\x9d) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that\xc2\xa0Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 1:15 PM Eastern Time.\nSoleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.
  • The company\xe2\x80\x99s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program.
  • For more information, please visit www.soleno.life .\n'

Saniona Launches New Video Series to Highlight the Impact of Prader-Willi Syndrome and Hypothalamic Obesity on Patients and Caregivers

Retrieved on: 
Monday, May 10, 2021

The company\xe2\x80\x99s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain.

Key Points: 
  • The company\xe2\x80\x99s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain.
  • Ultimately CP survivors with hypothalamic injury report at least three times higher 20-year mortality than CP survivors without hypothalamic injury.
  • Many HO patients are treated with approaches used for general obesity such as surgery, medication and lifestyle counseling, but these are often ineffective.
  • It occurs most often in children and older adults, creating a burden for both patients and families.\n'

Saniona to Present at Multiple Upcoming Investor Conferences

Retrieved on: 
Monday, April 26, 2021

The company\xe2\x80\x99s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain.

Key Points: 
  • The company\xe2\x80\x99s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain.
  • Saniona\xe2\x80\x99s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated.
  • Lead candidate SAN711 is entering Phase 1 for rare neuropathic disorders, with SAN903 for rare inflammatory and fibrotic disorders advancing through preclinical development.
  • Led by an experienced scientific and operational team, Saniona has an established research organization in Copenhagen, Denmark and is building its corporate office in the Boston, Massachusetts area, U.S.

Saniona Announces Partnership with the Foundation for Prader-Willi Research (FPWR) to Support its Prader-Willi Syndrome (PWS) Clinical Trial with Tesomet

Retrieved on: 
Monday, April 19, 2021

\xe2\x80\x9cWe look forward to working with FPWR to gather this feedback and to increase awareness of our clinical trial.\xe2\x80\x9d\nSaniona\xc2\xa0previously evaluated Tesomet in a randomized, double-blind, placebo-controlled Phase 2a trial in adults and adolescents with PWS.

Key Points: 
  • \xe2\x80\x9cWe look forward to working with FPWR to gather this feedback and to increase awareness of our clinical trial.\xe2\x80\x9d\nSaniona\xc2\xa0previously evaluated Tesomet in a randomized, double-blind, placebo-controlled Phase 2a trial in adults and adolescents with PWS.
  • Adult patients receiving Tesomet achieved a statistically significant reduction in hyperphagia, as well as a clinically meaningful reduction in body weight at a dose of 0.5 mg per day.
  • The company\xe2\x80\x99s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain.
  • Saniona is advancing Tesomet for hypothalamic obesity and Prader-Willi syndrome, two severe rare disorders characterized by obesity and loss of appetite control.

2021 Global Prader-Willi Syndrome Clinical Trial Pipeline Highlights - ResearchAndMarkets.com

Retrieved on: 
Friday, March 26, 2021

The "Global Prader-Willi Syndrome Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Prader-Willi Syndrome Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides the most up-to-date information on key pipeline products in the global Prader-Willi Syndrome market.
  • It covers emerging therapies for Prader-Willi Syndrome in active clinical development stages including early and late stage clinical trials.
  • The report provides Prader-Willi Syndrome pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Saniona publishes its year-end report for 2020

Retrieved on: 
Wednesday, March 17, 2021

Saniona received written feedback fromthe U.S. Food and Drug Administration (FDA) regarding pre-Investigational New Drug (IND) submissions for Tesomet in Prader-Willi syndrome (PWS) and HO.

Key Points: 
  • Saniona received written feedback fromthe U.S. Food and Drug Administration (FDA) regarding pre-Investigational New Drug (IND) submissions for Tesomet in Prader-Willi syndrome (PWS) and HO.
  • Saniona refined its pipeline, regaining exclusive, global rights to its GABAa5 negative allosteric modulator program from Boehringer Ingelheim, which terminated this collaboration for strategic reasons.This does not impact the 2020 collaboration between Saniona and Boehringer Ingelheim, which remains ongoing.
  • Saniona received an upfront payment of approximately USD 2.9 million (SEK 24.2 million) relating to Novartiss acquisition of Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3%.
  • Based on this feedback, Saniona is proceeding with plans to initiate a Phase 2b study in HO in the first half of this year.